AR094879A1 - ORAL FORMULATION AND SUSPENSION OF AN ONCOLOGICAL DRUG - Google Patents

ORAL FORMULATION AND SUSPENSION OF AN ONCOLOGICAL DRUG

Info

Publication number
AR094879A1
AR094879A1 ARP140100584A ARP140100584A AR094879A1 AR 094879 A1 AR094879 A1 AR 094879A1 AR P140100584 A ARP140100584 A AR P140100584A AR P140100584 A ARP140100584 A AR P140100584A AR 094879 A1 AR094879 A1 AR 094879A1
Authority
AR
Argentina
Prior art keywords
suspension
oral formulation
oncological drug
oncological
drug
Prior art date
Application number
ARP140100584A
Other languages
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR094879A1 publication Critical patent/AR094879A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Formulación oral y suspensión de una composición farmacéutica que comprende sonidegib que es útil para tratar enfermedades relacionadas con la actividad de la vía de señalización del Erizo que incluyen, por ejemplo, cánceres del cerebro, músculo, piel y próstata; meduloblastoma; adenocarcinomas pancreáticos; y carcinomas de pulmón de células pequeñas.Oral formulation and suspension of a pharmaceutical composition comprising sonidegib that is useful for treating diseases related to the activity of the Hedgehog signaling pathway including, for example, cancers of the brain, muscle, skin and prostate; medulloblastoma; pancreatic adenocarcinomas; and small cell lung carcinomas.

ARP140100584A 2013-02-25 2014-02-25 ORAL FORMULATION AND SUSPENSION OF AN ONCOLOGICAL DRUG AR094879A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361768803P 2013-02-25 2013-02-25

Publications (1)

Publication Number Publication Date
AR094879A1 true AR094879A1 (en) 2015-09-02

Family

ID=50288200

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100584A AR094879A1 (en) 2013-02-25 2014-02-25 ORAL FORMULATION AND SUSPENSION OF AN ONCOLOGICAL DRUG

Country Status (11)

Country Link
US (2) US9943520B2 (en)
EP (1) EP2958550B1 (en)
JP (1) JP6310484B2 (en)
AR (1) AR094879A1 (en)
AU (1) AU2014220339B2 (en)
ES (1) ES2935528T3 (en)
IL (2) IL240629B (en)
PL (1) PL2958550T3 (en)
TW (2) TWI696470B (en)
WO (1) WO2014128661A1 (en)
ZA (1) ZA201506012B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10266523B2 (en) 2015-03-30 2019-04-23 Crystal Pharmatech Co., Ltd. Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof
WO2017163258A1 (en) * 2016-03-22 2017-09-28 Msn Laboratories Private Limited Process for the preparation of n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2- methyl-4'-(trifiuoromethoxy) [1,1' -biphenyi]-3-carboxamide and its polymorphs thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA831186B (en) * 1982-03-22 1983-11-30 Upjohn Ltd Gelled pge2/triacetin solutions
PE20110292A1 (en) * 2008-09-17 2011-05-17 Novartis Ag SALTS OF N- [6- (CIS-2,6-DIMETHYL-MORPHOLIN-4-IL) -PYRIDIN-3-IL] -2-METHYL-4 '- (TRIFLUORO-METOXY) - [1,1'-BIPHENYL ] -3-CARBOXAMIDE
AR077490A1 (en) * 2009-07-21 2011-08-31 Novartis Ag TOPICAL PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF A HYPERPROLIFERATIVE SKIN CONDITION
EP2471791B1 (en) * 2009-08-26 2014-11-12 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
JP2012094104A (en) * 2010-09-29 2012-05-17 Omron Corp Information processing device and method, and program

Also Published As

Publication number Publication date
JP2016510724A (en) 2016-04-11
IL276838A (en) 2020-10-29
WO2014128661A1 (en) 2014-08-28
JP6310484B2 (en) 2018-04-11
ES2935528T3 (en) 2023-03-07
TWI684462B (en) 2020-02-11
IL276838B (en) 2021-05-31
US10426781B2 (en) 2019-10-01
IL240629B (en) 2020-09-30
US9943520B2 (en) 2018-04-17
US20160008369A1 (en) 2016-01-14
AU2014220339A1 (en) 2015-09-17
AU2014220339B2 (en) 2016-12-01
EP2958550B1 (en) 2022-08-17
US20180071305A1 (en) 2018-03-15
TW202019392A (en) 2020-06-01
TW201442738A (en) 2014-11-16
PL2958550T3 (en) 2023-01-16
IL240629A0 (en) 2015-10-29
TWI696470B (en) 2020-06-21
EP2958550A1 (en) 2015-12-30
ZA201506012B (en) 2020-01-29

Similar Documents

Publication Publication Date Title
NI201600071A (en) AUTOTAXIN INHIBITOR COMPOUNDS
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
CO2017001493A2 (en) Kits comprising tigit inhibitors and anticancer agents
BR112015019995A2 (en) THERAPEUTIC COMBINATION INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR THE TREATMENT OF CANCER
PH12016500582A1 (en) Heterocyclic compounds and uses thereof
CR20140108A (en) CYCLOPROPANOAMINE COMPOUND
CL2015003801A1 (en) Antibody formulations and methods
DOP2015000185A (en) FUSIONATED PYRIMIDINES REPLACED WITH TRIFLUOROMETILO AND ITS USES
AR090774A1 (en) DIHYDRATE OF A BENZOTIOPHENE COMPOUND OR ONE OF ITS SALTS AND PROCESS FOR PRODUCTION
MX2019006878A (en) Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug.
NI201600070A (en) AUTOTAXIN TETRAYCLIC INHIBITORS
EA201691032A1 (en) IZHOCHROMEN DERIVATIVES AS PHOSFOINOSYTID-3-KINAZ INHIBITORS
MX2016000794A (en) High potency pancreatin pharmaceutical compositions.
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
MX2016000480A (en) High potency pancreatin pharmaceutical compositions.
EA201792571A1 (en) THERAPEUTIC APPLICATION OF L-4-CHLOROKINURENIN
MX2016006603A (en) Piperidine compounds having multimodal activity against pain.
MX2016006087A (en) Rapidly disintegrating formulations and methods of use.
EA201591450A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING GLYCOSAMINO GLYCAN
AR094879A1 (en) ORAL FORMULATION AND SUSPENSION OF AN ONCOLOGICAL DRUG
MX2020006075A (en) Bendamustine pharmaceutical compositions.
IN2013MU03118A (en)
DOP2015000290A (en) BENZOXAZOLES REPLACED
PH12020500472A1 (en) Autotaxin inhibitor compounds
TR201716203A1 (en) New umeclidinium formulations.

Legal Events

Date Code Title Description
FC Refusal